Dehydroemetine
| Dehydroemetine |
|---|
| MEBADIN® Prescribing Information |
| General Information |
| Clinical Information |
| Dosage and Administration |
| Precautions |
| Use in Pregnancy |
| Adverse Effects |
| Drug Interactions |
| Storage |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Dehydroemetine is a synthetically produced antiprotozoal agent similar to emetine in its anti-amoebic properties and structure (they differ only in a double bond next to the ethyl substituent), but it produces fewer side effects. In the United States, it is manufactured by Roche.
Category
Amebicide
US Brand Names
Mebadin®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | How Supplied | Labels and Packages
Mechanism of action
Its exact mechanism is not known, but in vitro it inhibits translocation.[1]
References
- ↑ Abdi, Y. A. (1995). Handbook of drugs for tropical parasitic infections. Washington, DC: Taylor & Francis. p. 47. ISBN 0-7484-0168-7.